



FOR IMMEDIATE RELEASE:

Symple Surgical Inc. Completes Series A Common Stock Financing

Menlo Park, California – October 31, 2013 – In a tough investment climate for medical device companies¹, Symple Surgical Inc. announced today that it has completed a Series A Common Stock financing, totaling approximately \$1.9 million to fund its novel microwave catheter technology platform. Daniel J. Kasprzyk, founder of Machine Solutions Inc. and entrepreneur with multiple device related companies, led the round that includes participation by multiple angel investors. Gentry Capital, Chicago, Illinois and Cunningham Mott PC served as financial and legal advisors for this transaction.

Dr. Gary M. Ansel, MD, FACC, observes: “Hypertension is a worldwide medical and economic burden. Renal sympathetic denervation is a unique therapy that has demonstrated benefit in patients that are not well treated with medical therapy alone. The Symple Surgical microwave system is evaluating a unique energy source in an effort to improve on safety to the normal vessel wall while providing a high level of success in controlling hypertension. I am excited to evaluate the clinical potential of this unique approach.”

Symple Surgical is developing a therapeutic microwave energy device for renal sympathetic denervation, to effectively modulate hyperactive sympathetic nerve signals.

- Renal sympathetic denervation is a novel therapy that addresses severe hypertension and other chronic diseases.
- The sympathetic nerves located along the renal artery wall play a critical role in controlling blood pressure. When overactive these nerves contribute to Cardiovascular Hypertension.
- Renal sympathetic denervation has been demonstrated to reduce blood pressure in patients who are not adequately treated by pharmacological and other medical therapies^{2,3}.

“Symple Surgical is committed to developing a unique device which is safe and effective for treating patients with resistant Hypertension, easy to use for the physician, and provides targeted therapy without damaging healthy tissue,” stated Randy Preston, Chief Operating Officer at Symple Surgical. “Initial pre-clinical testing has validated our core concepts and we will continue to refine our technology as we work towards a First-in-Man study by mid-2014.”

About Symple Surgical Inc.

Symple Surgical, Inc. is a privately-held company with engineering and product development offices in Menlo Park, CA. Symple Surgical is focused on developing a medical device to help millions of patients living with resistant hypertension through renal sympathetic denervation by delivering microwave energy at the location of the sympathetic nerves while minimizing thermal exposure to non-targeted areas.

Two proven medical device entrepreneurs, Daniel J. Kasprzyk and Randy Preston, founded Symple Surgical. With 25 years in the medical device industry Mr. Kasprzyk has executive experience in startup and multinational business platform companies and holds numerous patents in the device and equipment space. Mr. Preston’s experience includes 10 years international business development and project management in the interventional medical device field. He is uniquely positioned to lead the product development team as they refine and launch the novel Symple Surgical microwave device platform.

For more information:
Randy Preston, Chief Operating Officer
(415) 686-1284

The information provided herein does not constitute an offer to sell or a solicitation of an offer to buy securities. Securities transactions processed through Gentry Securities, LLC, member FINRA/SIPC.



¹ Wall Street Journal, November 5, 2013 "[Funding Dries up of Medical Startups](#)"

² Urban D, Ewen S, Ukena C, Linz D, Böhm M, Mahfoud F 2013 [Treating resistant hypertension: role of renal denervation](#) Integr Blood Press Control Volume 2013:6 Pages 119 - 128

³ Neergaard L, Perrone M May. 28, 2012 [New Approach Tested Hard-to-Treat Hypertension](#), AP The Big Story